A Phase 3 interventional study of Placebo and AMG 162 / Denosumab in Breast Cancer, Low Bone Mineral Density and Osteopenia, sponsored by Amgen. Completed. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-17.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing denosumab in Breast Neoplasms — none open to participants now, 3 under way, 2 of them phase 3. Denosumab · Breast Neoplasms.
Among the 24 studies testing denosumab in Breast Neoplasms, this one is the 8th largest by enrollment, is one of 2 that started in 2004, is one of 9 in phase 3, and was the 1st registered.
14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.
Browse Breast Neoplasms studies →None of the 24 studies testing denosumab in Breast Neoplasms is open now. The open studies under Breast Neoplasms, anywhere →
Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 252 is above the median of 72 across 10,911 interventional studies indexed under Breast Neoplasms.
Median enrollment 53 across the 24 interventional studies. Of the 17 that completed or were terminated, 12 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 24 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
30 studies in Breast Neoplasms by Amgen: none open now, 1 under way, 1 of them phase 3. Of 29 finished, 16 (55%) have results posted.
Among the 30 studies in Breast Neoplasms by Amgen, this one is the 11th largest by enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2004, is one of 10 in phase 3, and was the 3rd registered.
Amgen’s Breast Neoplasms studies by the year they started, since 2002.
1 of the studies testing denosumab in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04711109Phase 3Alliance for Clinical Trials in OncologyStudying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation | 2027-07 |
Add it to your calendar (.ics) → With an account.
Among the 24 studies testing denosumab in Breast Neoplasms, from their registry updates:
Among Amgen’s 30 in Breast Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this trial is to evaluate AMG 162 in the treatment of bone loss in subjects undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer.
Other criteria also apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: AMG 162 / Denosumab
Drug: Placebo
60 mg (1.0 mL) administered subcutaneously every six months, beginning on Study Day 1, for a total treatment period of 24 months
Drug page: Denosumab
60 mg (1.0 mL) administered subcutaneously every six months, beginning on Study Day 1, for a total treatment period of 24 months
Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.
Time frame: 12 months
Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 6
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.
Time frame: 6 months
Total Hip Bone Mineral Density Percent Change From Baseline at Month 12
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.
Time frame: 12 months
Total Hip Bone Mineral Density Percent Change From Baseline at Month 6
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.
Time frame: 6 months
Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 12
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.
Time frame: 12 months
Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 6
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.
Time frame: 6 months
| Milestone | Denosumab 60 mg Q6M | Placebo |
|---|---|---|
| Started | 127 | 125 |
| Completed | 106 | 99 |
| Not completed | 21 | 26 |
| Withdrew: Adverse event | 0 | 2 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 3 |
| Withdrew: Withdrawal by subject | 11 | 9 |
| Withdrew: Disease progression | 1 | 3 |
| Withdrew: Ineligibility determined | 4 | 4 |
| Withdrew: Noncompliance | 2 | 4 |
| Withdrew: Other | 2 | 1 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.
| Percent Change from Baseline | Denosumab 60 mg Q6M | Placebo |
|---|---|---|
| Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12 | 4.8 (4.3 to 5.4) | -.7 (-1.3 to -.1) |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.
| Percent Change from Baseline | Denosumab 60 mg Q6M | Placebo |
|---|---|---|
| Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 6 | 3.7 (3.2 to 4.2) | -.6 (-1.1 to -.1) |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.
| Percent Change from Baseline | Denosumab 60 mg Q6M | Placebo |
|---|---|---|
| Total Hip Bone Mineral Density Percent Change From Baseline at Month 12 | 3.1 (2.6 to 3.5) | -.7 (-1.1 to -.2) |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.
| Percent Change from Baseline | Denosumab 60 mg Q6M | Placebo |
|---|---|---|
| Total Hip Bone Mineral Density Percent Change From Baseline at Month 6 | 2.3 (1.9 to 2.8) | -.4 (-.8 to .1) |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.
| Percent Change from Baseline | Denosumab 60 mg Q6M | Placebo |
|---|---|---|
| Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 12 | 1.9 (1.1 to 2.6) | -.6 (-1.4 to .2) |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.
| Percent Change from Baseline | Denosumab 60 mg Q6M | Placebo |
|---|---|---|
| Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 6 | 1.2 (.5 to 1.9) | -.9 (-1.6 to -.2) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 11/120 (9.2%) | 108/120 (90%) |
| Denosumab 60 mg Q6M | — | 19/129 (14.7%) | 117/129 (90.7%) |
| Event | Placebo | Denosumab 60 mg Q6M |
|---|---|---|
| CholelithiasisHepatobiliary disorders | 2/120 | 0/129 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/120 | 2/129 |
| Atrial fibrillationCardiac disorders | 1/120 | 0/129 |
| Cardiac failure congestiveCardiac disorders | 1/120 | 0/129 |
| Myocardial ischaemiaCardiac disorders | 1/120 | 0/129 |
| GoitreEndocrine disorders | 1/120 | 0/129 |
| FaecalomaGastrointestinal disorders | 1/120 | 0/129 |
| Large intestine perforationGastrointestinal disorders | 1/120 | 0/129 |
| CholecystitisHepatobiliary disorders | 1/120 | 1/129 |
| PneumoniaInfections and infestations | 1/120 | 0/129 |
| Event | Placebo | Denosumab 60 mg Q6M |
|---|---|---|
| ArthralgiaMusculoskeletal and connective tissue disorders | 30/120 | 31/129 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 14/120 | 19/129 |
| FatigueGeneral disorders | 17/120 | 17/129 |
| Back painMusculoskeletal and connective tissue disorders | 15/120 | 18/129 |
| InsomniaPsychiatric disorders | 14/120 | 12/129 |
| ConstipationGastrointestinal disorders | 11/120 | 15/129 |
| CoughRespiratory, thoracic and mediastinal disorders | 5/120 | 13/129 |
| NauseaGastrointestinal disorders | 11/120 | 10/129 |
| DepressionPsychiatric disorders | 11/120 | 7/129 |
| MyalgiaMusculoskeletal and connective tissue disorders | 5/120 | 11/129 |
| Age, Continuous(Years) | Denosumab 60 mg Q6M | Placebo | Total |
|---|---|---|---|
| Mean | 59.2 ± 8.9 | 59.7 ± 9.7 | 59.5 ± 9.3 |
| Sex: Female, Male(Participants) | Denosumab 60 mg Q6M | Placebo | Total |
|---|---|---|---|
| Female | 127 | 125 | 252 |
| Male | 0 | 0 | 0 |
No study locations are listed for this record.
Ran from Oct 2004 to primary completion in May 2007, 31 months.
Results were first posted in Jan 2010, 2 years 8 months after primary completion. A results delay was requested in Nov 2009.
Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 31 months is below that.
Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Denosumab